Drugs / RYZ801
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06726161 | Sep 2025 → Jun 2030 expected | hepatocellular carcinoma | RayzeBio, Inc. | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RYZ801 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06726161 ↗ |